Contractile Dysfunction Irrespective of the Mutant Protein in Human Hypertrophic Cardiomyopathy With Normal Systolic Function
Authors:
- E. Rosalie PaalberendsEPE. Rosalie Paalberends
- Aref NajafiANAref Najafi
- Michelle MichelsMMMichelle Michels
- Sakthivel SadayappanSakthivel Sadayappan
- Lucie CarrierLCLucie Carrier
- Nicky M. BoontjeNBNicky M. Boontje
- Diederik W.D. KusterDKDiederik W.D. Kuster
- Marjon van SlegtenhorstMSMarjon van Slegtenhorst
- Dennis DooijesDDDennis Dooijes
- Cris dos RemediosCRCris dos Remedios
- Folkert J. Ten CateFCFolkert J. Ten Cate
Open Access
- 1 January 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 5 (1) , 36-46
Abstract
Background—: Hypertrophic cardiomyopathy (HCM), typically characterized by asymmetrical left ventricular hypertrophy, frequently is caused by mutations in sarcomeric proteins. We studied if changes in sarcomeric properties in HCM depend on the underlying protein mutation. Methods and Results—: Comparisons were made between cardiac samples from patients carrying a MYBPC3 mutation (MYBPC3 mut ; n=17), mutation negative HCM patients without an identified sarcomere mutation (HCM mn ; n=11), and nonfailing donors (n=12). All patients had normal systolic function, but impaired diastolic function. Protein expression of myosin binding protein C (cMyBP-C) was significantly lower in MYBPC3 mut by 33±5%, and similar in HCM mn compared with donor. cMyBP-C phosphorylation in MYBPC3 mut was similar to donor, whereas it was significantly lower in HCM mn . Troponin I phosphorylation was lower in both patient groups compared with donor. Force measurements in single permeabilized cardiomyocytes demonstrated comparable sarcomeric dysfunction in both patient groups characterized by lower maximal force generating capacity in MYBPC3 mut and HCM mn, compared with donor (26.4±2.9, 28.0±3.7, and 37.2±2.3 kN/m 2 , respectively), and higher myofilament Ca 2+ -sensitivity (EC 50 =2.5±0.2, 2.4±0.2, and 3.0±0.2 μmol/L, respectively). The sarcomere length-dependent increase in Ca 2+ -sensitivity was significantly smaller in both patient groups compared with donor (ΔEC 50 : 0.46±0.04, 0.37±0.05, and 0.75±0.07 μmol/L, respectively). Protein kinase A treatment restored myofilament Ca 2+ -sensitivity and length-dependent activation in both patient groups to donor values. Conclusions—: Changes in sarcomere function reflect the clinical HCM phenotype rather than the specific MYBPC3 mutation. Hypocontractile sarcomeres are a common deficit in human HCM with normal systolic left ventricular function and may contribute to HCM disease progression.Keywords
This publication has 49 references indexed in Scilit:
- More severe cellular phenotype in human idiopathic dilated cardiomyopathy compared to ischemic heart diseaseJournal of Muscle Research and Cell Motility, 2010
- Protein kinase A–induced myofilament desensitization to Ca2+ as a result of phosphorylation of cardiac myosin–binding protein CJournal of General Physiology, 2010
- Normal passive viscoelasticity but abnormal myofibrillar force generation in human hypertrophic cardiomyopathyJournal of Molecular and Cellular Cardiology, 2010
- How do hypertrophic cardiomyopathy mutations affect myocardial function in carriers with normal wall thickness? Assessment with cardiovascular magnetic resonanceJournal of Cardiovascular Magnetic Resonance, 2010
- Myocardial Fibrosis as an Early Manifestation of Hypertrophic CardiomyopathyNew England Journal of Medicine, 2010
- Effect of troponin I Ser23/24 phosphorylation on Ca2+-sensitivity in human myocardium depends on the phosphorylation backgroundJournal of Molecular and Cellular Cardiology, 2010
- Protein kinase C α and ε phosphorylation of troponin and myosin binding protein C reduce Ca2+ sensitivity in human myocardiumBasic Research in Cardiology, 2009
- Echocardiographic Strain Imaging to Assess Early and Late Consequences of Sarcomere Mutations in Hypertrophic CardiomyopathyCirculation: Cardiovascular Genetics, 2009
- Progress With Genetic CardiomyopathiesCirculation: Heart Failure, 2009
- Cardiac myosin binding protein c phosphorylation is cardioprotectiveProceedings of the National Academy of Sciences, 2006